Arm Band Tested in New Study for Blood Glucose Monitoring

临床研究
Most people with Type 1 or Type 2 diabetes measure their blood glucose levels multiple times daily with an invasive finger-prick test. The prick test stings a bit for a short time, but the aggravation of acquiring, carrying, and remembering to use the gear is even more irksome. Lakka Health, a Finish health tech company, filed a study design to evaluate a new, non-invasive sensor-based technology to detect low blood sugar this spring. DCB (Diabetes Center BerneDiabetes Center Berne) Research AG is the study sponsor. The study will be conducted in collaboration with University Hospital Inselspital, Berne. Instead of measuring blood glucose levels directly, the Lakka study will use the company’s Sorku wearable armband device to measure volatile organic compounds (VOCs) discharged through the skin. According to Lakka Health, when the blood glucose level falls too low or drops fast, diabetics emit specific VOCs. Lakka patented a temperature cycle operation (TCO) that boosts the sensitivity and selectivity of extremely low-concentrated VOCs by ramping the temperature. The clinical study’s first aim is to ascertain the VOC signal characteristics the Sokru device detects when Type 1 diabetes patients fast, inject insulin, and intake glucose. The study’s second objective is to determine if VOC concentrations correspond to various glycemia levels, from hypoglycemia to hyperglycemia. It’s important to note that the Sokru test is a first-level clinical study, with just 10 participants in a single group model. If Lakka Health’s Sokru first clinical evaluation results indicate valid and reliable associations between blood glucose levels and specific VOC emissions through patients’ skin, further testing will be in order. The potential upside is a passive, non-invasive blood glucose testing method that could simplify the lives of people with diabetes. Or not. We look forward to seeing the results of the Sorku study.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI,赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台,以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。